Forthcoming

Kinerja Keuangan Perusahaan Farmasi BUMN dan Non-BUMN Sebelum dan Selama Pandemi

Authors

  • Michelia Yemima Hardwi Atmaja Fakultas Ekonomika dan Bisnis, Universitas Kristen Satya Wacana
  • Arthik Davianti Departemen Akuntansi, Fakultas Ekonomika dan Bisnis, Universitas Kristen Satya Wacana

DOI:

10.33395/owner.v6i3.874

Keywords:

Financial Performance, Financial Ratios, Pharmaceutical Industry

Abstract

Since the emergence of COVID-19 in Indonesia, several corporate sectors in Indonesia have had their operational activities disrupted, which has caused a decline in revenue. However, there are industrial sectors that have benefited from the COVID-19 pandemic. One of them is the pharmaceutical industry. This study aims to determine the financial performance of public and private pharmaceutical companies before and during the pandemic. This research is descriptive quantitative research with the data source being secondary data. The data analysis technique uses net profit margin and returns on equity as profitability ratio, current ratio and quick ratio as liquidity ratio, total asset turnover and inventory turnover as activity ratio, debt to equity ratio, and debt to asset ratio as solvency ratios. The results show that private companies have better financial performance than public companies. Sido Muncul company has the best liquidity and solvency performance among other companies. Merck Indonesia has the best profitability performance, while Pyridam Farma has the best activity performance. In contrast, Indofarma has the worst performance among others even though in terms of activity performance, Indofarma is the most efficient company in selling products.

 

Sejak kemunculan COVID-19 di Indonesia, beberapa sektor perusahaan di Indonesia terganggu aktivitas operasionalnya yang menyebabkan penurunan pendapatan. Namun, terdapat sektor industri yang diuntungan dari adanya pandemi COVID-19. Salah satunya industri farmasi. Penelitian bertujuan untuk mengetahui kinerja keuangan perusahaan farmasi BUMN dan Non-BUMN sebelum dan selama pandemi. Penelitian ini merupakan penelitian kuantitatif deskriptif dengan sumber data yang digunakan berupa data sekunder. Teknik analisis data menggunakan analisis rasio profitabilitas yaitu net profit margin dan return on equity, rasio likuiditas yaitu current ratio dan quick ratio, rasio aktivitas yaitu total asset turnover dan inventory turnover, dan rasio solvabilitas yaitu debt to equity ratio dan debt to asset ratio. Hasil penelitian menunjukkan bahwa perusahaan Non-BUMN memiliki kinerja keuangan perusahaan yang lebih baik dari perusahaan BUMN. Hal ini dapat dilihat bahwa perusahaan Sido Muncul memiliki kinerja likuiditas dan solvabilitas paling baik diantara perusahaan lainnya. Kinerja profitabilitas paling baik dimiliki oleh perusahaan Merck Indonesia sedangkan Pyridam Farma memiliki kinerja aktivitas terbaik diantara lainnya. Sementara Indofarma memiliki kinerja paling buruk diantara lainnya meskipun pada kinerja aktivitas, Indofarma merupakan perusahaan yang paling efisien dalam menjual produknya.

Downloads

Download data is not yet available.

        Plum-X Analityc

References

Afif, & Hudi, A. T. (2021). Kilas Balik Kinerja APBN 2020. Kementerian Keuangan Republik Indonesia. http://www.anggaran.kemenkeu.go.id/in/post/kilas-balik-kinerja-apbn-2020

Anthony, R. N., Hawkins, R., Merchant, K., & Singh, P. (2019). Accounting: Text and Cases (Thirteenth). McGraw-Hill.

Biro Humas Kemnaker. (2020). Survei Kemnaker?: 88 Persen Perusahaan Terdampak Pandemi Covid-19. Kementerian Ketenagakerjaan Republik Indonesia. https://kemnaker.go.id/news/detail/survei-kemnaker-88-persen-perusahaan-terdampak-pandemi-covid-19

Burkhardt, J. H., & Wheeler, J. R. C. (2013). Indicators for Acute Care Hospitals. Journal of Health Care Finance, 39(March), 1–13.

Chinedu Innocent, E., Ifeoma Mary, O., & Monday Matthew, O. (2013). Financial Ratio Analysis as a Determinant of Profitability in Nigerian Pharmaceutical Industry. International Journal of Business and Management, 8(8), 107–117. https://doi.org/10.5539/ijbm.v8n8p107

Daryanto, C., & Daryanto, W. M. (2019). Financial performance analysis and evaluation of pharmaceutical companies in Indonesia. International Journal of Innovation, Creativity and Change, 6(3), 207–224.

Devi, S., Warasniasih, N. M. S., & Masdiantini, P. R. (2020). The Impact of COVID-19 Pandemic on the Financial Performance of Firms on the Indonesia Stock Exchange. Journal of Economics, Business, & Accountancy Ventura, 23(2), 226–242. https://doi.org/10.14414/jebav.v23i2.2313

Division of Viral Diseases. (2021). Benefits of Getting a COVID-19 Vaccine. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/vaccine-benefits.html#:~:text=COVID-19 vaccination will be,these measures are not enough.

Endri, E., Susanti, D., Hutabarat, L., Simanjuntak, T. P., & Handayani, S. (2020). Financial performance evaluation: Empirical evidence of pharmaceutical companies in Indonesia. Systematic Reviews in Pharmacy, 11(6), 803–816. https://doi.org/10.31838/srp.2020.6.117

Fahmi, I. (2012). Analisis Kinerja Keuangan. Alfabeta.

Fahmi, I. (2014). Manajemen Keuangan Perusahaan dan Pasar Modal (Pertama). Wacana Media.

Fatihudin, D., Jusni, & Mochklas, M. (2018). How measuring financial performance. International Journal of Civil Engineering and Technology, 9(6), 553–557.

Hanafi, M. H., & A. Halim. (2016). Analisis Laporan Keuangan (Kelima). Penerbit UPP STIM YKPN.

Hery. (2016). Analisis Laporan Keuangan (Integrated). PT Grasindo.

Kafi, M. S. (2018). Analisis Rasio Likuiditas, Rentabilitas Dan Solvabilitas Untuk Mengukur Kinerja Keuangan. JMK (Jurnal Manajemen Dan Kewirausahaan), 3(38), 49–60.

Kieso, D. E., Weygandt, J. J., & Warfield, T. D. (2020). Intermediate Accounting: IFRS Edition (4th Editio). John Wiley & Sons, Inc.

Kusumastuty, I., Saptantinah, D., & Astuti, P. (2013). Penilaian Kinerja Keuangan Perusahaan Melalui Analisis Rasio Pada Perusahaan Telekomunikasi. Jurnal Ilmiah Akuntansi Dan Bisnis, 8(1), 45–51.

Lan, J. (2012). Financial Ratios for Analyzing a Company’s Strengths and Weaknesses. AAII. https://www.aaii.com/journal/article/16-financial-ratios-for-analyzing-a-companys-strengths-and-weaknesses

Lessambo, F. I. (2018). Financial Statements Analysis and Reporting. Palgrave Macmillan.

Lukman, D. (2013). Manajemen Perbankan. Ghalia Indonesia.

Mardiyani, M. (2017). Analisis Perbandingan Kinerja Keuangan Perusahaan Farmasi Milik BUMN dan Swasta. Jurnal Inspirasi Bisnis Dan Manajemen, 1(1). https://doi.org/http://dx.doi.org/10.33603/jibm.v1i1.486

Megaladevi, P. (2015). A study on financial performance analysis of the select Paper Company with special reference to Tamil Nadu Newsprint and papers limited. International Journal of Recent Research Aspects, 2(4), 22–24.

Mittal, S., & Sharma, D. (2021). The impact of COVID-19 on stock returns of the Indian healthcare and pharmaceutical sector. Australasian Accounting, Business and Finance Journal, 15(1 Special Issue), 5–21. https://doi.org/10.14453/aabfj.v15i1.2

Munawir, S. (2014). Analisis Laporan Keuangan (Keempat). LIBERTY.

Prasetya, V. (2021). Analisis Kinerja Keuangan Perusahaan Sebelum Dan Saat Pandemi Covid 19 Pada Perusahaan Farmasi Yang Tercatat Di Bursa Efek Indonesia. Cerdika: Jurnal Ilmiah Indonesia, 1(5), 579–587. https://cerdika.publikasiindonesia.id/index.php/cerdika/article/view/92

Prasetyo, W. B. (2019). Divestasi Picu Lonjakan Laba PT Merck di 2018. BERITASATU. https://www.beritasatu.com/ekonomi/552075/divestasi-picu-lonjakan-laba-pt-merck-di-2018

Purwanto, H., & Daryanto, W. M. (2020). Financial Performance Analysis of Pharmaceutical Listed Companies Four Years Before and After Universal Healthcare Coverage Initiation in Indonesia (2010 - 2018). International Journal of Business, Economics, and Law, 21(3), 30–46.

Robinson, T. R. (2020). International Financial Statement Analysis. Wiley.

Rosa, N. La. (2021). Analyzing Financial Performance Using Integrated Ratio Analysis. Routledge Taylor & Francis Group.

Saubani, A. (2020). Empat Sektor Ekonomi yang Paling Tertekan Pandemi Covid-19. Republika.Id. https://republika.co.id/berita/q83llp409/empat-sektor-ekonomi-yang-paling-tertekan-pandemi-covid19

Sheela, S. C. (2012). Financial Performance of Pharmaceutical Industry in India using DuPont Analysis. European Journal of Business and Management, 4(14), 84–91.

Spiceland, J. D., Nelson, M. W., & Thomas, W. B. (2018). Intermediate Accounting (Tenth Edit). McGraw-Hill.

Subramanyam, K. R. (2014). Financial Statement Analysis (Eleventh). McGraw-Hill.

Sugianto, D. (2020). Erick Beberkan Alasan Swasta Dilarang Impor Vaksin Corona. Detik Finance. https://finance.detik.com/industri/d-5277837/erick-beberkan-alasan-swasta-dilarang-impor-vaksin-corona

Syahran, R., Hakim, D. B., & Sukandar, D. (2016). the Evaluation on the Financial Performance of Paper and Pulp Companies in Indonesia. Indonesian Journal of Business and Entrepreneurship, 2(3), 187–196. https://doi.org/10.17358/ijbe.2.3.187

Ulya, F. N., & Setiawan, S. R. D. (2020). BI: Kontraksi Terus Berlanjut, Pertumbuhan Ekonomi RI Menurun. Kompas.Com. https://money.kompas.com/read/2020/06/22/173622226/bi-kontraksi-terus-berlanjut-pertumbuhan-ekonomi-ri-menurun?page=all

Weygandt, J. J., Kimmel, P. D., & Kieso, D. E. (2018). Financial Accounting with International Reporting Standard (4th ed.). Wiley.

Weygandt, Jerry J., Keiso, D. E., & Kimmel, P. D. (2015). Accounting Principle (12th ed.). John Wiley & Sons, Inc.

Widyatuti, M. (2017). Analisa Kritis Laporan Keuangan. CV. Jakad Media Nusantara Surabaya.

Published

2022-06-07

How to Cite

Atmaja, M. Y. H., & Davianti, A. (2022). Kinerja Keuangan Perusahaan Farmasi BUMN dan Non-BUMN Sebelum dan Selama Pandemi. Owner : Riset Dan Jurnal Akuntansi, 6(3). https://doi.org/10.33395/owner.v6i3.874